Mainz Biomed to Present at the H.C. Wainwright Bioconnect Virtual Conference
January 11 2022 - 03:01AM
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),
a molecular genetics diagnostic company specializing in the early
detection of cancer, announced today that Guido Baechler, Chief
Executive Officer, will present at the H.C. Wainwright Bioconnect
Virtual Conference taking place on January 10-13, 2022.
To access Mainz’s presentation at the H.C. Wainwright Bioconnect
Virtual Conference, please visit www.hcwevents.com/bioconnect to
register for the event.
About ColoAlertColoAlert detects
colorectal cancer (CRC) via a simple-to-administer test with a
sensitivity and specificity nearly as high as the invasive
colonoscopy*. The test utilizes proprietary methods to analyze cell
DNA for specific tumor markers combined with the fecal
immunochemistry test (FIT) and is designed to detect tumor DNA and
CRC cases in their earliest stages. The product is CE-IVD marked
(complying with EU safety, health and environmental requirements)
and is transitioning to compliance with IVDR. The product is
commercially available in a selection of countries in the European
Union. Mainz Biomed currently distributes ColoAlert through a
number of clinical affiliates. Once approved in the U.S., the
Company’s commercial strategy is to establish scalable distribution
through a collaborative partner program with regional and national
laboratory service providers across the country.*Dollinger MM et
al. (2018)
About Colorectal CancerColorectal
cancer (CRC) is the second most lethal cancer in the U.S. and
Europe, but also the most preventable with early detection
providing survival rates above 90%. Annual testing costs per
patient are minimal, especially when compared to late-stage
treatments of CRC which cost patients an average of $38,469 per
year. The American Cancer Society estimates that in 2021 there will
be approximately 149,500 new cases of colon and rectal cancer in
the U.S. with 52,980 resulting in death. Recent FDA decisions
suggest that screening with stool DNA tests such as ColoAlert in
the US should be conducted once every three years starting at age
45. Currently, there are 112 million Americans aged 50+, a total
that is expected to increase to 157 million within 10 years.
Appropriately testing these US-based 50+ populations every three
years as prescribed equates to a US market opportunity of
approximately $3.7 Billion per year.
About Mainz Biomed N.V.Mainz
Biomed develops market-ready molecular genetic diagnostic solutions
for life-threatening conditions. The Company’s flagship product is
ColoAlert, an accurate, non-invasive, and easy-to-use early
detection diagnostic test for colorectal cancer. ColoAlert is
currently marketed across Europe with an FDA clinical study and
submission process intended to be launched in the first half of
2022 for U.S. regulatory approval. Mainz Biomed’s product candidate
portfolio includes PancAlert, an early-stage pancreatic cancer
screening test based on Real-Time Polymerase Chain Reaction-based
(PCR) multiplex detection of molecular-genetic biomarkers in stool
samples, and the GenoStick technology, a platform being developed
to detect pathogens on a molecular genetic basis.
For more information, please visit
www.mainzbiomed.com
For media enquiries, please
contact press@mainzbiomed.com
For investor enquiries, please
contact ir@mainzbiomed.com
Forward-Looking StatementsCertain
statements made in this press release are “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words
such as “anticipate”, “believe”, “expect”, “estimate”, “plan”,
“outlook”, and “project” and other similar expressions that predict
or indicate future events or trends or that are not statements of
historical matters. These forward-looking statements reflect the
current analysis of existing information and are subject to various
risks and uncertainties. As a result, caution must be exercised in
relying on forward-looking statements. Due to known and unknown
risks, actual results may differ materially from the Company’s
expectations or projections. The following factors, among others,
could cause actual results to differ materially from those
described in these forward-looking statements: (i) the failure to
meet projected development and related targets; (ii) changes in
applicable laws or regulations; (iii) the effect of the COVID-19
pandemic on the Company and its current or intended markets; and
(iv) other risks and uncertainties described herein, as well as
those risks and uncertainties discussed from time to time in other
reports and other public filings with the Securities and Exchange
Commission (the “SEC”) by the Company. Additional information
concerning these and other factors that may impact the Company’s
expectations and projections can be found in its initial filings
with the SEC, including its Prospectus filed on October 12, 2021
and amended on October 25, 2021 and November 1, 2021. The Company’s
SEC filings are available publicly on the SEC’s website at
www.sec.gov. Any forward-looking statement made by us in this press
release is based only on information currently available to Mainz
Biomed and speaks only as of the date on which it is made. Mainz
Biomed undertakes no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise, except as required by law.
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Feb 2024 to Mar 2024
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Mar 2023 to Mar 2024